The development of vaccines: How the past led to the future

Nature Reviews Microbiology

Volumn 9, Issue 12, 2011, Pages 889-893

  Plotkin, Stanley A ^a   Plotkin, Susan L ^b  

^a Vaxconsult   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INACTIVATED VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; PLASMID DNA; POLIOMYELITIS VACCINE; TOLL LIKE RECEPTOR 4;

BCG VACCINATION; CELL CULTURE; CELL EXPANSION; DNA SHUFFLING; GENETIC ENGINEERING; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEROEPIDEMIOLOGY; TRANSCRIPTOMICS; YELLOW FEVER FLAVIVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL INFECTIONS; CELL CULTURE TECHNIQUES; GENETIC ENGINEERING; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VACCINES; VIRUS DISEASES;

ANIMALIA;

EID: 81255141781     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2668     Document Type: Review

References (79)

1. Rappuoli, R., Black, S. & Lambert, P. H. Vaccine discovery and translation of new vaccine technology. Lancet 378, 360-368 (2011).
2. Nakaya, H. I. et al. Systems biology of seasonal influenza vaccination in humans. Nature Immunol. 12, 786-795 (2011).
3. Pulendran, B. & Ahmed, R. Immunological mechanisms of vaccination. Nature Immunol. 131, 509-517 (2011).
4. Plotkin, S. A. Vaccines: the fourth century. Clin. Vaccine Immunol. 16, 1709-1719 (2009).
5. von Bubnoff, A. An immunological rationale for vaccines. IAVI Rep. 14, 4-7 (2010).
6. Pead, P. J. Benjamin Jesty: Dorset's Vaccination Pioneer (Timefile Books, Chichester, 2009).
7. Jenner, E. An Inquiry into the Causes and Effects of the Variolae Vaccinae (Low, London, 1798).
8. Bazin, H. Vaccination: a History. From Lady Montagu to Genetic Engineering. (John Libbey Eurotext, Montrouge, 2011).
9. Copeman, S. M. The Milroy Lectures on the natural history of vaccinia. Lecture III. Lancet 151, 1375-1382 (1898).
10. Dudgeon, J. A. Development of smallpox vaccine in England in the eighteenth and nineteenth centuries. BMJ 1, 1367-1372 (1963).
11. Gubser, C. et al. Poxvirus genomes: a phylogenetic analysis. J. Gen. Virol. 85, 105-117 (2004). (Pubitemid 38128875)
12. Tulman, E. R. et al. Genome of horsepox virus. J. Virol. 80, 9244-9258 (2006). (Pubitemid 44359997)
13. Pasteur, L. De l'atténuation du virus du choléra des poules. C. R. Acad. Sci. 91, 673-680 (1880) (in French).
14. Cadeddu, A. Pasteur et le choléra des poules: révision critique d'un récit historique. Hist. Philos. Life Sci. 7, 87-104 (1985) (in French).
15. Pasteur, L., Chamberland, C.-E, & Roux, E. Sur la vaccination charbonneuse. C. R. Acad. Sci. 92, 1378-1383 (1881) (in French).
16. Pasteur, L. Méthode pour prévenir la rage après morsure. C. R. Acad. Sci. 101, 765-772 (1885) (in French).
17. Salmon, D. E. The theory of immunity from contagious diseases. Proc. Am. Assoc. Adv. Sci. 35, 262-266 (1886).
18. Pfeiffer, R. & Kolle, W. Experimentelle untersuchungen zur frage der schutzimpfung des menschen gegen typhus adbdominalis. Dtsch. Med. Wochenschr. 22, 735-737 (1896) (in German).
19. Kolle, W. Zur aktiven immunisierung der menschen gegen Cholera. Zentralbl. Bakteriol. Abt. Jena 19, 97-104 (1896) (in German).
20. Haffkine, W. M. Remarks on the plague prophylactic fluid. BMJ 1, 1461-1462 (1897).
21. Roux, E. & Yersin, A. Contribution à l'étude de la diphtérie. Ann. Inst. Pasteur (Paris) 2, 629-661 (1888) (in French).
22. von Behring, E. & Kitasato, S. Über das zustandekommen der diphtherie-immunität und der tetanus-immunität bie tieren. Dtsch. Med. Wochenschr. 16, 1113-1114 (1890) (in German).
23. von Behring, E. Serum therapy in therapeutics and medical science. Nobelprize.org [online], http://www. nobelprize.org/nobel-prizes/medicine/ laureates/1901/behring-lecture.html (2011).
24. Ehrlich, P. On immunity with special reference to cell life. Proc. R. Soc. Lond. 66, 424-448 (1899).
25. Glenny, A. T. & Hopkins, B. E. Diphtheria toxoid as an immunising agent. Br. J. Exp. Pathol. 4, 283-288 (1923).
26. Ramon, G. Sur le pouvoir floculant et sur les propriétés immunisantes d'une toxine diphtérique rendue anatoxique (anatoxine). C R. Acad. Sci. Paris 177, 1338-1340 (1923) (in French).
27. Calmette, A. & Guérin, C. Contribution à l'étude de l'immunité antituberculose chez les bovidés. Ann. Inst. Pasteur (Paris) 28, 329-337 (1914) (in French).
28. Calmette, A. L'Infection Bacillaire et la Tuberculose 4th edn (Masson et Cie, Paris, 1936) (in French).
29. Theiler, M. & Smith, H. H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787-800 (1937).
30. Lloyd, W., Theiler, M. & Ricci, N. I. Modification of virulence of yellow fever virus by cultivation in tissues in vitro. Trans. R. Soc. Trop. Med. Hyg. 29, 481-529 (1936).
31. Monath, T. P. in History of Vaccine Development (ed. Plotkin, S. A.) 109-135 (Springer, New York, 2011).
32. Madsen, T. Whooping cough: its bacteriology, diagnosis, prevention and treatment. Boston Med. Surg. J. 192, 50-60 (1925).
33. Madsen, T. Vaccination against whooping cough. JAMA 101, 187-188 (1933).
34. Sato, Y. et al. Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect. Immun. 31, 1223-1231 (1981). (Pubitemid 11155491)
35. Edwards, K. M., Decker, M. D., Mortimer, E. A. Jr. in Vaccines 3rd edn (eds Plotkin, S. A. & Orenstein, W. A.) 293-344 (W. B. Saunders, Philadelphia, 1999).
36. Smith, W., Andrewes, C. H. & Laidlaw, P. P. A virus obtained from influenza patients. Lancet 222, 66-68 (1933).
37. Francis, T. Jr & Magill, T. P. Vaccination of human subjects with virus of human influenza. Proc. Soc. Exp. Biol. Med. 33, 604-606 (1936).
38. Smorodintsev, A. A., Tushinsky, M. D., Drobyshevskaya, A. I. & Korovin, A. A. Investigation on volunteers infected with the influenza virus. Am. J. Med. Sci. 194, 159-170 (1937).
39. Maassab, H. F. & DeBorde, D. C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3, 355-369 (1985). (Pubitemid 16201989)
40. Enders, J. F., Weller, T. H. & Robbins, F. C. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109, 85-87 (1949).
41. Salk, J. E. et al. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nat ons Health 44, 563-570 (1954).
42. Sabin, A. B., Hennessen, W. A. & Winsser, J. Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunological types. J. Exp. Med. 99, 551-576 (1954).
43. Koprowski, H., Jervis, G. A. & Norton, T. W. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am. J. Hyg. 55, 108-126 (1952).
44. Hammon, W. M., Coriell, L. L., Wehrle, P. F. & Stokes, J. Jr. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. JAMA 151, 1272-1285 (1953).
45. Katz, S. L. et al. Studies on an attenuated measles virus vaccine. VIII. General summary and evaluation of results of vaccine. N. Engl. J. Med. 263, 180-184 (1960).
46. Hilleman, M. R., Buynak, E. B., Weibel, R. E. & Stokes, J. Jr. Live attenuated mumps-virus vaccine. N. Engl. J. Med. 278, 227-232 (1968).
47. Meyer, H. M. & Parkman, P. D. Rubella vaccination: a review of practical experience. JAMA 215, 613-619 (1971).
48. Prinzie, A., Huygelen, C., Gold, J., Farquhar, J. & McKee, J. Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain. Am. J. Dis. Child. 118, 172-177 (1969).
49. Plotkin, S. A., Farquhar, J. D., Katz, M. & Buser, F. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am. J. Dis. Child. 118, 178-185 (1969).
50. Takahashi, M. et al. Development of a live attenuated varicella vaccine. Biken J. 18, 25-33 (1975).
51. Takaku, K. et al. Japanese encephalitis purified vaccine. Biken J. 11, 25-39 (1968).
52. Benda, R. & Danes, L. Study of the possibility of preparing a vaccine against tick-borne encephalitis, using tissue culture methods. V. Experimental data for the evaluation of the efficiency of formol treated vaccines in laboratory animals. Acta Virol. 5, 37 (1961).
53. Germanier, R. & Fürer, E. Isolation and characterization of Gal E mutant Ty21a of Salmonella typhi: a candidate for a live, oral typhoid vaccine. J. Infect. Dis. 131, 553-558 (1975).
54. Avery, O. T. & Goebel, W. F. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54, 437-447 (1931).
55. Parke, J. C. Jr et al. Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg County, North Carolina. J. Infect. Dis. 136, S51-S57 (1977).
56. Gotschlich, E. C., Liu, T. Y. & Artenstein, M. S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 129, 1349-1365 (1969).
57. Austrian, R. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89, 184-192 (1976).
58. Austrian, R. in History of Vaccine Development (ed. Plotkin, S. A.) 83-90 (Springer, New York, 2011).
59. Schneerson, R., Barrera, O., Sutton, A. & Robbins, J. B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152, 361-376 (1980). (Pubitemid 10037059)
60. English, M. et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19, 1232-1238 (2001). (Pubitemid 32008291)
61. Eskola, J. & Antilla, M. Pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 18, 543-551 (1999). (Pubitemid 29277622)
62. Landy, J. Studies of Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am. J. Hyg. 50, 52-62 (1954).
63. Robbins, J. D. & Robbins, J. B. Reexamination of the protective role of the capsular polysaccharide Vi antigen of Salmonella typhi. J. Infect. Dis. 150, 436-439 (1984).
64. Provost, P. J. et al. An inactivated hepatitis A vaccine of cell culture origin. J. Med. Virol. 19, 23-31 (1986). (Pubitemid 16142968)
65. Wiktor, T. J., Plotkin, S. A. & Koprowski, H. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev. Biol. Stand. 40, 3-9, 1978.
66. Beardsley, T. Biotechnology: Cohen-Boyer patent finally confirmed. Nature 311, 3 (1984).
67. Hilleman, M. R. et al.in Viral Hepatitis (eds Vyas, G. N., Cohen, S. N. & Schmid, R.) 525-527 (Franklin Institute Press, Philadelphia, 1978).
68. McAleer. W. J. et al. Human hepatitis B vaccine from recombinant yeast. Nature 307, 178-180 (1984). (Pubitemid 14132908)
69. Zhou, J., Sun, X. Y., Stenzel, D. J. & Frazer, I. H. Expression of vaccinia recombinant HPV 16 Li and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185, 251-257 (1991).
70. Kirnbauer, R. et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180-12184 (1992). (Pubitemid 23004809)
71. Sigal, L. H. et al. Vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N. Engl. J. Med. 339, 216-222 (1998). (Pubitemid 28350163)
72. Steere, A. C. et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339, 209-215 (1998). (Pubitemid 28350162)
73. Clark, H. F., Offit, P. A., Plotkin, S. A. & Heaton, P. M. The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr. Inf. Dis. J. 25, 577-583 (2006). (Pubitemid 43995352)
74. Bernstein, D. I. et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 354, 287-290 (1999). (Pubitemid 29348737)
75. Metchnikoff, E. Immunity in the Infective Diseases (Cambridge Univ. Press, Cambridge, UK,1905).
76. Miller, J. A scientific odyssey: unravelling the secrets of the thymus. Med. J. Aust. 183, 582-584 (2005). (Pubitemid 43009418)
77. Cooper, M. D., Cain, W. A., Van Alten, P. J. & Good, R. A. Development and function of the immunoglobulin producing system. I. Effect of bursectomy at different stages of development on germinal centers, plasma cells, immunoglobulins and antibody production. Int. Arch. Allergy Appl. Immunol. 35, 242-252 (1969).
78. Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271-2284 (2005).
79. Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055-1065 (2010).